

1 ***Wolbachia*-induced inhibition of O'nyong nyong virus in *Anopheles***
2 **mosquitoes is mediated by Toll signaling and modulated by cholesterol**

3

4 Sujit Pujhari^{1,#}, Grant L Hughes^{1,2#}, Nazzy Pakpour³, Yasutsugu Suzuki^{1,5}, Jason
5 L Rasgon^{1*}.

6

7 ¹The Department of Entomology, Center for Infectious Disease Dynamics, and
8 the Huck Institutes of the Life Sciences, Pennsylvania State University, University
9 Park, PA, USA

10 ²Departments of Vector Biology and Tropical Disease Biology, Centre for
11 Neglected Tropical Disease, Liverpool School of Tropical Medicine, Liverpool,
12 United Kingdom

13 ³Novozymes Inc., Davis, CA, USA

14 ⁴ Center for Marine Environmental Studies, Ehime University, Matsuyama, Japan

15 [#]These authors contributed equally to this work.

16 ^{*}Correspondence: jlr54@psu.edu

17

18 Running title: *Wolbachia* blocks O'nyong nyong virus in *Anopheles*

19

20 Keywords: *Wolbachia*, O'nyong nyong virus, pathogen interference, *Anopheles*,
21 mosquito, *Drosophila*, *Alphavirus*, RNA virus, TOLL pathway, immune
22 suppression, cholesterol, metabolic competition.

23

24 ABSTRACT

25 Enhanced host immunity and competition for metabolic resources are two main
26 competing hypotheses for the mechanism of *Wolbachia*-mediated pathogen
27 inhibition in arthropods. Using an *Anopheles* mosquito - somatic *Wolbachia*
28 infection - O'nyong nyong virus (ONNV) model, we demonstrate that the
29 mechanism underpinning *Wolbachia*-mediated virus inhibition is up-regulation of
30 the Toll innate immune pathway. However, the viral inhibitory properties of
31 *Wolbachia* were abolished by cholesterol supplementation. This result was due
32 to *Wolbachia*-dependent cholesterol-mediated suppression of Toll signaling
33 rather than competition for cholesterol between *Wolbachia* and virus. The
34 inhibitory effect of cholesterol was specific to *Wolbachia*-infected *Anopheles*
35 mosquitoes and cells. These data indicate that both *Wolbachia* and cholesterol
36 influence Toll immune signaling in *Anopheles* mosquitoes in a complex manner
37 and provide a functional link between the host immunity and metabolic
38 competition hypotheses for explaining *Wolbachia*-mediated pathogen
39 interference in mosquitoes. In addition, these results provide a mechanistic
40 understanding of the mode of action of *Wolbachia*-induced pathogen blocking in
41 Anophelines, which is critical to evaluate the long-term efficacy of control
42 strategies for malaria and *Anopheles*-transmitted arboviruses.

43

44

45

46

47 HIGHLIGHTS.

- 48 • *Wolbachia* inhibits O'nyong nyong virus (ONNV) in *Anopheles* mosquitoes.
- 49 • Enhanced Toll signaling is responsible for *Wolbachia*-induced interference of
- 50 ONNV.
- 51 • Cholesterol suppresses Toll signaling to modulate *Wolbachia*-induced ONNV
- 52 interference.

53

54 INTRODUCTION

55 *Wolbachia*-based strategies to control arthropod-borne diseases are gaining
56 considerable attention. After transinfection of *Wolbachia* into novel vectors
57 (reviewed in Hughes and Rasgon, 2014), the bacterium often impairs the hosts
58 ability to become infected with and transmit additional pathogens. While release
59 of *Wolbachia*-infected mosquitoes to control arbovirus transmission is well
60 underway (Hoffmann et al., 2011; Walker et al. 2011, Utarini et al. 2021, Collin et
61 al. 2022, Indriani et al. 2023), the molecular mechanisms underpinning
62 *Wolbachia*-mediated pathogen interference remain unclear. Two main theories
63 have been postulated regarding the mechanism of *Wolbachia*-mediated
64 pathogen interference; immune priming of the host by *Wolbachia* infection that
65 subsequently impedes other pathogens, or competition between *Wolbachia* and
66 pathogens for metabolic resources such as cholesterol (Frentiu 2017,
67 Geoghegan et al., 2017). While evidence exists to support both hypotheses (Bian
68 et al. 2010, Pan et al. 2012, Bourtzis et al., 2014; Rainey et al., 2014, Frentiu
69 2017, Geoghegan et al., 2017, Jiménez et al. 2021), unambiguous general
70 support for either hypothesis is yet to be provided. In addition, interference
71 mechanisms are likely to differ between insect hosts, *Wolbachia* strains,
72 pathogens, and the type of association (natural or artificial). Given that
73 *Wolbachia*-infected mosquitoes are currently being released into field populations
74 (Hoffmann et al., 2011; Walker et al. 2011, Collin et al. 2022, Utarini et al. 2021,
75 Indriani et al. 2023), there is a great urgency to understand the molecular
76 mechanisms underpinning these pathogen interference phenotypes.

77

78 In support of the hypothesis that immune priming by *Wolbachia* subsequently
79 impedes other pathogens, mosquitoes artificially infected with *Wolbachia* often
80 have enhanced innate immunity (Bian et al., 2010; Pan et al. 2012, Blagrove et
81 al., 2012; Kambris et al., 2009; Moreira et al., 2009, Hughes et al. 2011a, 2011b).
82 For example, in *Aedes aegypti* infected with the *wAlbB* *Wolbachia* strain,
83 elevated levels of reactive oxygen species (ROS) lead to upregulation of the Toll
84 pathway, decreasing mosquito susceptibility to dengue virus (Pan et al., 2012).
85 Similarly, *Anopheles stephensi* stably infected with *wAlbB* have higher ROS
86 levels compared to their uninfected counterparts (Bian et al., 2013), suggesting
87 that a similar mechanism might be occurring in Anopheline mosquitoes.
88 Additionally, ROS can directly inhibit *Plasmodium* development in *Anopheles*
89 (Luckhart et al., 2013; Molina-Cruz et al., 2008) .

90

91 While enhanced host immunity contributes to pathogen interference in
92 mosquitoes, this is likely not the sole mechanism by which *Wolbachia* inhibits
93 pathogens. In native *Wolbachia* associations in *Drosophila* where *Wolbachia*
94 does not alter basal immunity (Bourtzis et al., 2000; Xi et al., 2008), a protective
95 effect against viral pathogens is still observed (Bourtzis et al., 2000; Hedges et
96 al., 2008; Teixeira et al., 2008; Xi et al., 2008). For example, *Wolbachia* infection
97 in *Drosophila melanogaster* mutants deficient in Toll and IMD signaling still
98 resulted in impaired viral infections (Rances et al., 2013; Rances et al., 2012).
99 These studies suggest that immune induction is not the sole mechanism by

100 which *Wolbachia*-mediated pathogen protection occurs in Diptera. There is
101 mounting evidence that resource competition between *Wolbachia* and other
102 pathogens contributes to both pathogen interference (artificial associations that
103 block pathogen transmission) and pathogen protection (natural associations that
104 protect the host). In particular, competition for cholesterol, a common nutritional
105 requirement for both *Wolbachia* and viral and protozoan pathogens, may
106 modulate pathogen development. In mosquitoes, *Wolbachia* behaves as a
107 cholesterol heterotroph, depleting hosts cholesterol levels (Caragata et al., 2013).
108 *Wolbachia*-infected *Drosophila* that received cholesterol supplementation had
109 higher viral titers and increased virus-induced mortality (Caragata et al., 2013,
110 2014). These observations suggest that cholesterol can negatively impact the
111 protective effect of *Wolbachia* in insects; however, the molecular mechanisms
112 behind this effect remain elusive. Understanding the role of cholesterol in
113 *Wolbachia*-mediated pathogen interference is particularly critical in mosquitoes
114 as cholesterol is a natural component of human blood and is therefore ingested
115 as part of a blood meal.

116

117 Using the O'nyong nyong virus (ONNV) - somatic *Wolbachia* infection -
118 *Anopheles* mosquito system, we show that *Wolbachia* infection significantly
119 reduces ONNV levels in artificial transient *in vivo* and stable *in vitro* associations.
120 We investigated the molecular mechanisms underpinning *Wolbachia*-mediated
121 pathogen interference of ONNV in *Anopheles* and found that (1) Toll-based
122 immunity is central to protection and (2) manipulation of cholesterol levels

123 significantly modulates the effect of *Wolbachia* on viral titers as had been
124 previously observed in *Drosophila*. Strikingly, the increase in viral titers was an
125 effect of cholesterol-induced modulation of Toll signaling rather than nutritional
126 competition between *Wolbachia* and ONNV. These findings provide a functional
127 link between the two main current hypotheses regarding the molecular
128 mechanisms of *Wolbachia*-mediated pathogen interference in mosquitoes and
129 highlight the need for further research into the role of ingested human cholesterol
130 (and potentially other factors) on the vector competence of *Wolbachia*-infected
131 mosquitoes.

132

133 RESULTS.

134 ***Wolbachia* inhibits ONNV levels in cell lines and mosquitoes**

135 To determine if *Wolbachia*-mediated pathogen interference occurs during ONNV
136 infection in mosquitoes, we first challenged *An. gambiae* Sua5B cells which were
137 stably infected with either *Wolbachia* strain wMel from *D. melanogaster* or
138 *Wolbachia* strain wAlbB from *Aedes albopictus* (Rasgon et al. 2006) (Figure 1A).
139 Both strains of *Wolbachia* significantly inhibited infectious ONNV titers in the cells
140 (Figure 1B). This effect was density-dependent as evidenced by the increase in
141 ONNV titers following antibiotic treatment of wAlbB-infected Sua5B cells (Figures
142 1C).

143

144 In order to confirm our results *in vivo*, we established transient somatic
145 *Wolbachia* infections (wMel and wAlbB) in female adult *An. gambiae* and *An.*

146 *stephensi* mosquitoes by intrathoracic microinjection (Hughes et al., 2011b; Jin et
147 al., 2009) and challenged mosquitoes 7 days later with an infectious blood meal
148 containing ONNV. In both *An. gambiae* and *An. stephensi* we observed
149 significant reductions in ONNV infectious viral titers in *Wolbachia*-infected
150 individuals compared to uninfected controls (Figure 2). Given the similarities
151 between the two different strains of *Wolbachia* in our experiments, further
152 characterization studies were conducted with *wAlbB*.

153

154 ***Wolbachia* upregulates *Anopheles* host genes antagonistic to ONNV**

155 The Toll and IMD pathways are the main innate immune pathways in *Anopheles*
156 mosquitoes (Christophides et al. 2002, Carissimo et al. 2014). Waldock and
157 colleagues (2012) identified several *Anopheles* host genes which were
158 antagonistic to ONNV, including genes in the Toll innate immunity signaling
159 pathway such as *ML1* and *LYSC4*. As the Toll pathway has been shown to
160 contribute to *Wolbachia* blocking of dengue virus in *Aedes aegypti* (Pan et al.
161 2012) we sought to determine if this immune pathway contributed to *Wolbachia*-
162 mediated blocking of ONNV in *Anopheles*. We used RNA interference (RNAi) to
163 knock down (KD) expression of key Toll and IMD pathway genes (including those
164 identified by Waldock et al. to be involved in ONNV modulation) in *wAlbB*-
165 infected *An. gambiae* cells, and quantified the effect on ONNV titers. We
166 observed that KD of the Toll pathway genes *LYSC4*, *ML1*, *TOLL5A*, or the double
167 KD of *ML1* and *TOLL5A* significantly increased ONNV titer in *Wolbachia*-infected
168 cells (Figure 3A), indicating these genes influence the *Wolbachia* interference

169 phenotype. No effect on ONNV titers was observed after KD of *IMD*, suggesting
170 this pathway is not involved in the *Wolbachia* interference phenotype in
171 *Anopheles* (Figure 3A). We further confirmed our results by reactivating the Toll
172 pathway downstream of *ML1* and *TOLL5A* by KD of the negative regulator *cactus*
173 in conjunction with KD of TOLL or ML1. KD of *cactus* restored the protective
174 effect of *Wolbachia* against ONNV (Figure 3A).

175

176 **Cholesterol inhibits *Wolbachia*-induced activation of Toll signaling in** 177 ***Anopheles* cells**

178 To determine the effects of cholesterol supplementation on *Wolbachia*-mediated
179 ONNV interference, we supplemented *wAlbB*-infected and uninfected cells with
180 cholesterol and then challenged them with ONNV. Cholesterol supplementation
181 did not significantly alter ONNV titer levels in *Wolbachia*-uninfected Sua5B cells.
182 However, the protective effect of *Wolbachia*-infection against ONNV infection was
183 lost in a dose-dependent manner following cholesterol supplementation (Figure
184 3B).

185

186 Because we had evidence for both TOLL-based innate immunity and cholesterol
187 in mediating *Wolbachia*-induced pathogen blocking, we examined if there was a
188 link between the two pathways. *Wolbachia* infection upregulated expression of
189 *TOLL5A* (Figure 3C). We found that cholesterol supplementation inhibited
190 *TOLL5A* expression in *Wolbachia*-infected cells, but had no significant effect in
191 *Wolbachia*-uninfected cells (Figure 3C). Conversely, treatment with the

192 cholesterol sequestering chemical methyl-beta-cyclodextrin (MBC) increased
193 *TOLL5A* expression in both *Wolbachia*-infected cells and uninfected cells, but the
194 effect was amplified by the presence of *Wolbachia* (Figure 3D). Neither
195 cholesterol supplementation nor sequestration affected expression of *IMD* in
196 either *Wolbachia*-infected or uninfected cells (Figures 3C, 3D).

197

198 To confirm the interplay between cholesterol and Toll-based immunity in
199 *Anopheles*, we undertook RNAi KDs in combination with cholesterol
200 supplementation in *wAlbB*-infected Sua5B cells. In the GFP control KD,
201 cholesterol ablated the protective effect of *Wolbachia* in a dose-dependent
202 manner. KD of *ML1* or *TOLL5A* uniformly increased ONNV titers in the no-
203 cholesterol control. KD of *cactus* (which activates Toll signaling downstream of
204 *TOLL5A* and *ML1*) restored the protective effect of *Wolbachia*, but as cholesterol
205 levels increased this effect was lost in a dose-dependent manner. KD of *IMD* in
206 the presence of cholesterol had no effect on ONNV levels (Fig 3E).

207

208 Finally, we confirmed this effect *in vivo* by feeding *An. gambiae* ONNV-infected
209 blood with or without cholesterol. Supplementation of cholesterol in an ONNV
210 infectious blood meal significantly reduced the protective phenotype of
211 *Wolbachia* in *Anopheles* mosquitoes but had no effect in *Wolbachia*-uninfected
212 mosquitoes (Figure 3F).

213

214 DISCUSSION

215 ***Wolbachia*-based suppression of ONNV replication through Toll-mediated**
216 **immunity is inhibited by cholesterol supplementation**

217 We have shown that *Wolbachia* inhibits development of ONNV in *Anopheles*
218 cells and mosquitoes, and demonstrated a link between the two main hypotheses
219 explaining *Wolbachia*-induced inhibition of pathogens (immune priming vs.
220 metabolic competition). As observed in other mosquito systems (Pan et al., 2011),
221 *Wolbachia* infection induced the Toll pathway which provided protection against
222 invading viruses. Similar to *Wolbachia*-mediated protection in *Drosophila*,
223 cholesterol supplementation in *Anopheles* dramatically ablates *Wolbachia*-
224 mediated viral interference. However, this effect seems to be due to repression of
225 TOLL signaling rather than metabolic competition for cholesterol between
226 *Wolbachia* and virus.

227

228 *Anopheles ML1* has been shown to interact with cytoplasmic actin to mediate
229 phagocytosis and killing of pathogens (Sandiford et al., 2015). In mammals, the
230 *ML1* homologue *MD2* is the co-receptor for *TLR-4*, where *TLR-4* and *MD2* form a
231 heteroduplex for binding of LPS and initiation of the pathway (Akashi et al., 2003;
232 da Silva Correia et al., 2001; da Silva Correia and Ulevitch, 2002; Muroi et al.,
233 2002). In contrast, Toll signaling in *Drosophila* is initiated by a complex of TOLL
234 and *spaetzle* (Alpar et al., 2018; Chowdhury et al., 2019). Our data suggest that
235 in addition to its previously described role in pathogen phagocytosis, *Anopheles*
236 *ML1* is likely also involved in Toll signaling, suggesting that Toll signaling in

237 *Anopheles* may be more similar to mammalian systems than to *Drosophila*.

238

239 In mammals, cholesterol is transported through the blood stream by two types of
240 carrier lipoproteins: low-density lipoprotein (LDL) and high-density lipoprotein
241 (HDL). Although both types of lipoproteins bind and transport cholesterol, they
242 have very different structures, functions, and immunomodulatory effects
243 (Michelsen et al., 2004; Xu et al., 2001). High levels of LDL have been
244 associated with diseases such as atherosclerosis and rheumatoid arthritis and
245 oxidized LDL can actually enhance TLR expression to induce a pro-inflammatory
246 immune response (Howell et al., 2011; Li et al., 2020; Xu et al., 2001). In contrast,
247 HDL has been shown to be anti-inflammatory and high levels of HDL in the blood
248 are associated with protection from cardiovascular disease (Ben-Aicha et al.,
249 2020; Catapano et al., 2014; Yu et al., 2010). Specifically, HDL has been shown
250 to impair Toll signaling in human macrophages (van der Vorst et al., 2017). This
251 is thought to occur, in part, due to the influence of cholesterol availability on the
252 formation of lipid rafts, which in turn can modulate the function of a variety of
253 immune receptors including TLRs (Fessler and Parks, 2011; Varshney et al.,
254 2016).

255

256 The main constituent of HDL, apolipoprotein A-I, is highly conserved across
257 vertebrate and invertebrate species, as is its ability to modulate cholesterol levels
258 (Bashtovyy et al., 2011; Collet et al., 1997). Lipid transport in most insects occurs
259 via lipophorin (Lp), which are a class of HDL (Chino et al. 1982, Shapiro 1988,

260 Atella et al. 1992), that contains three apolipoproteins (Apol, Apoll, ApolIII). Lps
261 are involved in the transport of lipids (like cholesterol) to and from the fat body,
262 the insect equivalent of the human liver (Marinotti et al., 2006). Both Lp and the
263 precursor to Apol/II have been documented to alter the immune response of
264 mosquitoes to pathogens and parasites (Cheon et al. 2006). Specifically, in *Ae.*
265 *aegypti* expression of Lp and the Lp receptor (LpRfb) were shown to be up-
266 regulated in response to *Plasmodium gallinaceum* infection and KD of Lp
267 significantly decreased oocyst development (Cheon et al., 2006). In *Anopheles*,
268 the precursor of Apol and Apoll appears to facilitate *Plasmodium* ookinete
269 invasion and oocyst development (Mendes et al., 2008). Similarly, KD of ApolIII of
270 *An. gambiae* also significantly increased *Plasmodium* development in the midgut
271 (Gupta et al., 2010). Therefore it is possible that ingested cholesterol bound to Lp
272 could be inhibiting Toll signaling pathways in *Wolbachia*-infected mosquitoes in a
273 manner similar to what has been previously described for HDL in humans.

274

275 While induced immunity does not appear to be important for *Wolbachia*-induced
276 pathogen protection in *Drosophila* (Rancès et al., 2012, 2013), our data suggest
277 immunity is a major driving force behind virus interference in *Anopheles*. Given
278 that Toll-based immunity also influences *Wolbachia*-mediated pathogen
279 interference in *Aedes aegypti* (Pan et al., 2012), this may suggest the
280 mechanism behind *Wolbachia* pathogen interference differs according to the
281 insect association. Differences could be attributed to pathogen interference
282 (interference of pathogens transmitted by an insect vector) compared to

283 pathogen protection (protection of the insect host from deleterious pathogens)
284 (Hughes and Rasgon, 2012), variation in the mechanism behind *Wolbachia*
285 strains (wAlbB compared to wMel-like strains), or host variation (mosquitoes
286 compared to flies). Variation in the protective effect of different strains of
287 *Wolbachia* has also been demonstrated (Chrostek et al., 2013).

288

289 From an applied perspective, *Wolbachia* is under investigation as a means to
290 control malaria in *Anopheles* mosquitoes (Hughes et al., 2011b, Bian et al., 2013,
291 Kambris et al. 2010, Jeffries et al. 2018, Walker et al. 2021). ONNV provides a
292 tractable *in vitro* system to investigate *Wolbachia*-mediated pathogen protection
293 in *Anopheles* mosquitoes, which may shed light on the mechanism involved in
294 the inhibition of *Plasmodium*. For example, silencing experiments indicate *ML1* is
295 antagonistic to *P. falciparum* yet is an agonist of *P. berghei* (Dong et al., 2006).
296 Up-regulation of this gene by wAlbB may explain the inhibitory effect on *P.*
297 *falciparum* (Bian et al., 2013; Hughes et al., 2011b) and enhancement of *P.*
298 *berghei* (Hughes et al., 2012) in transiently *Wolbachia*-infected *Anopheles*. The
299 findings that *Wolbachia* can be vertically transmitted in *Anopheles* after
300 manipulation of the native microbiota, the successful transinfection of *An.*
301 *stephensi*, and the identification of native *Wolbachia* strains in natural *Anopheles*
302 populations all further enhance the prospects of applied *Wolbachia* strategies in
303 *Anopheles* (Hughes et al., 2011b, Hughes and Rasgon 2014, Bian et al., 2013,
304 Kambris et al. 2010, Jeffries et al. 2018, Walker et al. 2021, Quek et al. 2022).
305 While issues surrounding *Wolbachia* pathogen enhancement in mosquitoes have

306 been raised (Hughes et al., 2014; Hughes et al., 2012; Murdock et al., 2014; Zele
307 et al., 2014), our results suggests this is not a concern for ONNV, and possibly
308 for other viruses capable of being transmitted by *Anopheles*, such as Mayaro
309 virus (Brustolin et al. 2018, Terradas et al. 2022).

310

311 EXPERIMENTAL PROCEDURES

312 **Mosquito and *Wolbachia* strains.**

313 *An. gambiae* mosquitoes (Keele strain) and *An. stephensi* (Liston strain) were
314 reared at 27°C and relative humidity of 85% with a 12-hour photoperiod and
315 offered 10% sucrose *ad libitum*. The *wAlbB* and the *wMel* strains of *Wolbachia*
316 were cultured in Sua5B cells as previously described (Rasgon et al., 2006).
317 Fluorescence *in situ* hybridization (FISH) visualization of endosymbionts and
318 qPCR/PCR detection in cell lines was carried out as previously described
319 (Rasgon et al. 2006, Hughes et al. 2011a, 2011b). To infect *Anopheles*
320 mosquitoes with *Wolbachia* the bacterium was purified from cells lines (Rasgon
321 et al., 2006) and 100nl *Wolbachia* suspension (10^8 bacteria/mL) or medium
322 (control) was intrathoracically microinjected into two day old anesthetized female
323 *Anopheles* mosquitoes (Hughes et al., 2011b; Jin et al., 2009).

324

325 **ONNV production, infection of cells and quantification.**

326 ONNV was generated from the full-length ONNV infectious clone p5'dsONN_{ic}.
327 RNA was *in vitro* transcribed from linearized *NotI* digested plasmid and purified
328 using RNeasy kits (Qiagen). Two micrograms RNA was transfected into Vero
329 cells using Lipofectamine LTX (Invitrogen) and grown as previously described
330 (Pujhari et al. 2022). Infected cells were cultured at 32°C with 5% CO₂ for 72
331 hours, then supernatant of the culture was harvested, stored at -80°C and used
332 when required for viral infections of cells or mosquitoes. Virus stock titers were
333 determined by FFU assays using Vero cells (Brault et al., 2004) as previously

334 described (Pujhari et al. 2022, Terradas et al. 2022).

335

336 Sua5B cells with and without *Wolbachia* (Rasgon et al., 2006) were infected with
337 ONNV to assess for *Wolbachia*-mediated pathogen interference. Cell lines were
338 cultured in 24-well plates at 25°C until confluent, then cell culture media
339 (Schneider's with 10% FBS) was removed and replaced with 500 µl fresh media
340 containing 1×10^7 FFU of virus and incubated at room temperature with constant
341 shaking for 2 hours. The media was then removed and replaced with fresh
342 Schneider's media with 10% FBS. Cells were cultured at 25°C for 5 days before
343 ONNV density in the supernatant was assessed via FFU assay as previously
344 described.

345

346 ***Wolbachia* density-dependence antibiotic assay**

347 wAlbB-infected Sua5B cells were treated with rifampicin for 4 h at 10 µg/ml, 5
348 µg/ml or 1 µg/ml, respectively (Lu et al., 2012). After treatment, cells were left to
349 recover for 24 hours then infected with ONNV, and ONNV in the supernatant
350 quantified by FFU assay 5 days later as described above.

351

352 **ONNV and *Wolbachia* infection of mosquitoes**

353 5 day-old *An. gambiae* and *An. stephensi* were infected with wAlbB or wMel by
354 intrathoracic injection as previously described (Jin et al. 2009, Hughes et al.
355 2011b) and *Wolbachia* allowed to establish for 7 days. Age-matched *Wolbachia*-
356 infected or uninfected (media injected) mosquitoes were orally infected with

357 ONNV by an infectious blood meal using a membrane feeder. Prior to feeding,
358 mosquitoes were starved overnight. 10^7 FFU ONNV was presented to
359 mosquitoes in blood warmed to 37°C for feeding. After blood feeding, unfed
360 mosquitoes were removed. Six days post feeding, mosquitoes were harvested,
361 homogenized individually and the lysate directly tested for infectious virus titer by
362 FFU assay as described above.

363

364 **Immune gene expression and RNAi in cell lines.**

365 Candidate mosquito genes that affect ONNV (*ML1* and *Lysc4*) were selected
366 from Waldock (2012) as well as canonical genes in the Toll and IMD signaling
367 pathways (*TOLL5A*, *IMD*), and the negative regulator of Toll (*cactus*). Gene
368 expression was normalized to the *S7* gene. To determine if these genes were
369 involved in the *Wolbachia*-mediated pathogen interference of ONNV, genes were
370 knocked down by RNAi in *wAlbB* infected Sua5B cells. Gene-specific double
371 stranded RNAs (dsRNAs) were synthesized using T7 MEGAscript kit (Ambion)
372 as described (Waldock et al., 2012), and transfected into cell lines. ONNV
373 infection of cell lines was performed 3 days post transfection and expression
374 levels of the target genes cells checked by qPCR to confirm knock down
375 (Supplementary Figure 1). Three days post ONNV infection, virus density was
376 quantified in the culture supernatants by FFU assay as described above. All
377 primer sequences are given in Supplementary Table 1.

378

379

380 **Effect of Cholesterol on ONNV and host gene expression in the context of**
381 ***Wolbachia* infection**

382 To examine the effect of cholesterol on *Wolbachia*-mediated pathogen
383 interference, cholesterol (250X Cholesterol lipid concentrate, #12531018,
384 Thermo Fisher) was supplemented to *wAlbB*-infected and uninfected Sua5B cells
385 (0, 1.5X, 3.0X, or 6.0X) and infected with ONNV as described above. Viral titers
386 in the supernatants were quantified 3 days post-infection by FFU assay as
387 described.

388

389 To examine the effect of cholesterol on candidate gene expression in *Wolbachia*
390 infected and uninfected backgrounds, *wAlbB*-infected and uninfected cells were
391 washed with FBS-free medium and incubated in FBS-free medium for 3h in 48-
392 well plate. Cells were then incubated with 3X cholesterol or 5mM methyl beta
393 cyclodextrin (M β C) (#377110050, Thermo Fisher) (doses chosen for biological
394 effectiveness but minimal cellular toxicity [Supplementary Figures 2 and 3]) for 4
395 hours, washed, then incubated with Schneider's media with 10% FBS at 25°C for
396 4 h prior to gene expression qPCR.

397

398 To assess the effect of cholesterol treatment on *Wolbachia* blocking of ONNV
399 and the role of candidate gene expression, we supplemented *wAlbB*-infected
400 cells with cholesterol (0, 1.5X, 3.0X, 6.0X) while simultaneously knocking down
401 *MDL1*, *TOLL5A*, *IMD*, or *cactus* or (compared to *GFP* control) using dsRNA as
402 described above. Cells were infected with ONNV 3 days post-cholesterol

403 treatment and dsRNA treatment and virus titer in the culture supernatants
404 quantified by FFU assay 3 days post-infection.

405

406 **Statistical analysis**

407 Data were analyzed by Analysis of variance (ANOVA) with Tukey's correction for
408 multiple comparisons.

409

410 AUTHOR CONTRIBUTIONS.

411 Conceived the study: GLH, JLR. Performed the experiments: SP, GLH, YS.
412 provided reagents: JLR. Analyzed the data: GLH, NP, JLR. Wrote the paper: SP,
413 GLH, NP, JLR.

414

415 ACKNOWLEDGEMENTS

416 We thank Dr. Brian Foy for providing the ONNV infectious clone, Dr. Christopher
417 Cirimotich, Ping Xue, and Rhiannon Schneider for technical support, Dr. Long
418 Cui for experimental assistance, and the Penn State Huck Institutes Microscopy
419 and Cytometry Facility for assistance with microscopy. This research was
420 supported by NIH grants R01AI116636, USDA Hatch funds (Project PEN04769),
421 a grant with the Pennsylvania Department of Health using Tobacco Settlement
422 Funds, and funds from the Dorothy Foehr Huck and J. Lloyd Huck endowment to
423 JLR. GLH was supported by grants from the BBSRC (BB/V011278/1,
424 BB/T001240/1, BB/X018024/1, and BB/W018446/1), the UKRI (20197), a Royal
425 Society Wolfson Fellowship (RSWF\R1\180013), the NIHR (NIHR2000907), and

426 the Bill and Melinda Gates Foundation (INV-048598).

427

428

429 **References.**

430 Akashi, S., Saitoh, S., Wakabayashi, Y., Kikuchi, T., Takamura, N., Nagai, Y.,
431 Kusumoto, Y., Fukase, K., Kusumoto, S., Adachi, Y., *et al.* (2003).
432 Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher
433 affinity than that with MD-2 or CD14. *J Exp Med* 198, 1035-1042.

434

435 Alpar, L., Bergantinos, C., and Johnston, L.A. (2018). Spatially Restricted
436 Regulation of Spatzle/Toll Signaling during Cell Competition. *Dev Cell* 46, 706-
437 719 e705.

438

439 Atella, G.C., Gondim, K.C., and Masuda, H. (1992). Transfer of phospholipids
440 from fat body to lipophorin in *Rhodnius prolixus*. *Arch Insect Biochem Physiol* 19,
441 133-144.

442

443 Bashtovyy, D., Jones, M.K., Anantharamaiah, G.M., and Segrest, J.P. (2011).
444 Sequence conservation of apolipoprotein A-I affords novel insights into HDL
445 structure-function. *J Lipid Res* 52, 435-450.

446

447 Ben-Aicha, S., Badimon, L., and Vilahur, G. (2020). Advances in HDL: Much
448 More than Lipid Transporters. *Int J Mol Sci* 21, 732.

449

450 Bian, G., Xu, Y., Lu, P., Xie, Y., and Xi, Z. (2010). The endosymbiotic bacterium
451 *Wolbachia* induces resistance to dengue virus in *Aedes aegypti*. *PLoS Pathog* 6,
452 e1000833.

453

454 Bian, G., Joshi, D., Dong, Y., Lu, P., Zhou, G., Pan, X., Xu, Y., Dimopoulos, G.,
455 and Xi, Z. (2013). *Wolbachia* invades *Anopheles stephensi* populations and
456 induces refractoriness to *Plasmodium* infection. *Science* 340, 748-751.

457

458 Blagrove, M.S., Arias-Goeta, C., Failloux, A.B., and Sinkins, S.P. (2012).
459 *Wolbachia* strain wMel induces cytoplasmic incompatibility and blocks dengue

460 transmission in *Aedes albopictus*. *Proc Natl Acad Sci U S A* 109, 255-260.

461

462 Bourtzis, K., Dobson, S.L., Xi, Z., Rasgon, J.L., Calvitti, M., Moreira, L.A., Bossin,
463 H.C., Moretti, R., Baton, L.A., Hughes, G.L., *et al.* (2014). Harnessing mosquito-
464 *Wolbachia* symbiosis for vector and disease control. *Acta Trop* 132 *Suppl*, S150-
465 163.

466

467 Bourtzis, K., Pettigrew, M.M., and O'Neill, S.L. (2000). *Wolbachia* neither induces
468 nor suppresses transcripts encoding antimicrobial peptides. *Insect Mol Biol* 9,
469 635-639.

470

471 Brustolin, M., Pujhari, S., Henderson, C.A., Rasgon, J.L. (2018). *Anopheles*
472 mosquitoes may drive invasion and transmission of Mayaro virus across
473 geographically diverse regions. *PLoS Negl Trop Dis* 12, e0006895

474

475 Caragata, E.P., Rances, E., Hedges, L.M., Gofton, A.W., Johnson, K.N., O'Neill,
476 S.L., and McGraw, E.A. (2013). Dietary cholesterol modulates pathogen blocking
477 by *Wolbachia*. *PLoS Pathog* 9, e1003459.

478

479 Caragata, E.P., Rances, E., O'Neill, S.L., and McGraw, E.A. (2014). Competition
480 for amino acids between *Wolbachia* and the mosquito host, *Aedes aegypti*.
481 *Microb Ecol* 67, 205-218.

482

483 Carissimo, G., Pondeville, E., McFarlane, M., Dietrich, I., Mitri, C., Bischoff, E.,
484 Antoniewski, C., Bourgouin, C., Failloux, A.B., Kohl, A., *et al.* (2015). Antiviral
485 immunity of *Anopheles gambiae* is highly compartmentalized, with distinct roles
486 for RNA interference and gut microbiota. *Proc Natl Acad Sci U S A* 112, E176-
487 185.

488

489 Catapano, A.L., Pirillo, A., Bonacina, F., and Norata, G.D. (2014). HDL in innate
490 and adaptive immunity. *Cardiovasc Res* 103, 372-383.

491

492 Cheon, H.M., Shin, S.W., Bian, G., Park, J.H., and Raikhel, A.S. (2006).
493 Regulation of lipid metabolism genes, lipid carrier protein lipophorin, and its
494 receptor during immune challenge in the mosquito *Aedes aegypti*. *J Biol Chem*
495 *281*, 8426-8435.

496

497 Chowdhury, M., Li, C.F., He, Z., Lu, Y., Liu, X.S., Wang, Y.F., Ip, Y.T., Strand, M.R.,
498 and Yu, X.Q. (2019). Toll family members bind multiple Spatzle proteins and
499 activate antimicrobial peptide gene expression in *Drosophila*. *J Biol Chem* *294*,
500 10172-10181.

501

502 Chino, H., and Downer, R.G.H. (1982). Insect hemolymph lipophorin: A
503 mechanism of lipid transport in insects. *Advances in Biophysics* *11*, 67-92.

504

505 Chrostek, E., Marialva, M.S., Esteves, S.S., Weinert, L.A., Martinez, J., Jiggins,
506 F.M., and Teixeira, L. (2013). *Wolbachia* variants induce differential protection to
507 viruses in *Drosophila melanogaster*: a phenotypic and phylogenomic analysis.
508 *PLoS Genet* *9*, e1003896.

509

510 Collet, X., Marcel, Y.L., Tremblay, N., Lazure, C., Milne, R.W., Perret, B., and
511 Weech, P.K. (1997). Evolution of mammalian apolipoprotein A-I and conservation
512 of antigenicity: correlation with primary and secondary structure. *J Lipid Res* *38*,
513 634-644.

514

515 Collin, M.H., Potter, G.E., Hitchings, M.D.T., Butler, E., Wiles, M., Kennedy, J.K.,
516 Pinto, S.B., Teixeira, A.B.M., Casanovas-Massana, A., Roupael, N.G., Deye,
517 G.A., Simmons, C.P., Moreira, L.A., Nogueira, M.L., Cummings, D.A.T., Ko, A.I.,
518 Teixeira, M.M., Edupuganti, S. (2022). EVITA Dengue: a cluster-randomized
519 controlled trial to Evaluate the efficacy of *Wolbachia*-Infected *Aedes aegypti*
520 mosquitoes in reducing the incidence of Arboviral infection in Brazil. *Trials*. *23*,185.

521

522 Christophides, G.K., Zdobnov, E., Barillas-Mury, C., Birney, E., Blandin, S., Blass,
523 C., Brey, P.T., Collins, F.H., Danielli, A., Dimopoulos, G., Hetru, C., Hoa, N.T.,
524 Hoffmann, J.A., Kanzok, S.M., Letunic, I., Levashina, E.A., Loukeris, T.G., Lycett,
525 G., Meister, S., Michel, K., Moita, L.F., Müller, H.M., Osta, M.A., Paskewitz, S.M.,
526 Reichhart, J.M., Rzhetsky, A., Troxler, L., Vernick, K.D., Vlachou, D., Volz, J., von
527 Mering, C., Xu, J., Zheng, L., Bork, P., Kafatos, F.C. (2002). Immunity-related
528 genes and gene families in *Anopheles gambiae*. *Science*. 298, 159-65.

529

530 da Silva Correia, J., Soldau, K., Christen, U., Tobias, P.S., and Ulevitch, R.J.
531 (2001). Lipopolysaccharide is in close proximity to each of the proteins in its
532 membrane receptor complex. transfer from CD14 to TLR4 and MD-2. *J Biol*
533 *Chem* 276, 21129-21135.

534

535 da Silva Correia, J., and Ulevitch, R.J. (2002). MD-2 and TLR4 N-linked
536 glycosylations are important for a functional lipopolysaccharide receptor. *J Biol*
537 *Chem* 277, 1845-1854.

538

539 Fessler, M.B., and Parks, J.S. (2011). Intracellular lipid flux and membrane
540 microdomains as organizing principles in inflammatory cell signaling. *J Immunol*
541 187, 1529-1535.

542

543 Frentiu, F.D. (2017). Lipids and Pathogen Blocking by *Wolbachia*. *Trends*
544 *Parasitol* 33, 916-917.

545

546 Geoghegan, V., Stainton, K., Rainey, S.M., Ant, T.H., Dowle, A.A., Larson, T.,
547 Hester, S., Charles, P.D., Thomas, B., Sinkins, S.P. (2017). Perturbed cholesterol
548 and vesicular trafficking associated with dengue blocking in *Wolbachia*-infected
549 *Aedes aegypti* cells. *Nat Commun* 8, 526.

550

551 Gupta, L., Noh, J.Y., Jo, Y.H., Oh, S.H., Kumar, S., Noh, M.Y., Lee, Y.S., Cha,
552 S.J., Seo, S.J., Kim, I., *et al.* (2010). Apolipoprotein III mediates antiplasmodial

553 epithelial responses in *Anopheles gambiae* (G3) mosquitoes. *PLoS One* 5,
554 e15410.

555

556 Hedges, L.M., Brownlie, J.C., O'Neill, S.L., and Johnson, K.N. (2008). *Wolbachia*
557 and virus protection in insects. *Science* 322, 702.

558

559 Hoffmann, A.A., Montgomery, B.L., Popovici, J., Iturbe-Ormaetxe, I., Johnson,
560 P.H., Muzzi, F., Greenfield, M., Durkan, M., Leong, Y.S., Dong, Y., *et al.* (2011).
561 Successful establishment of *Wolbachia* in *Aedes* populations to suppress dengue
562 transmission. *Nature* 476, 454-457.

563

564 Howell, K.W., Meng, X., Fullerton, D.A., Jin, C., Reece, T.B., and Cleveland, J.C.,
565 Jr. (2011). Toll-like receptor 4 mediates oxidized LDL-induced macrophage
566 differentiation to foam cells. *J Surg Res* 171, e27-31.

567

568 Hughes, G.L., Rivero, A., and Rasgon, J.L. (2014). *Wolbachia* can enhance
569 *Plasmodium* infection in mosquitoes: implications for malaria control? *PLoS*
570 *Pathog* 10, e1004182.

571

572 Hughes, G.L., and Rasgon, J.L. (2014). Transinfection: a method to investigate
573 *Wolbachia*-host interactions and control arthropod-borne disease. *Insect Mol Biol*
574 23, 141-151.

575

576 Hughes, G.L., Vega-Rodriguez, J., Xue, P., and Rasgon, J.L. (2012). *Wolbachia*
577 strain wAlbB enhances infection by the rodent malaria parasite *Plasmodium*
578 *berghei* in *Anopheles gambiae* mosquitoes. *Appl Environ Microbiol* 78, 1491-
579 1495.

580

581 Hughes, G.L., Ren, X., Ramirez, J.L., Sakamoto, J.M., Bailey, J.A., Jedlicka, A.E.,
582 and Rasgon, J.L. (2011a). *Wolbachia* infections in *Anopheles gambiae* cells:
583 transcriptomic characterization of a novel host-symbiont interaction. *PLoS*

584 Pathog 7, e1001296.

585

586 Hughes, G.L., Koga, R., Xue, P., Fukatsu, T., and Rasgon, J.L. (2011b).
587 Wolbachia infections are virulent and inhibit the human malaria parasite
588 Plasmodium falciparum in Anopheles gambiae. PLoS Pathog 7, e1002043.

589

590 Indriani, C., Tanamas, S.K., Khasanah, U., Ansari, M.R., Rubangi Tantowijoyo, W.,
591 Ahmad, R.A., Dufault, S.M., Jewell, N.P., Utarini, A., Simmons, C.P., and Anders,
592 K.L. (2023). Impact of randomised wmel Wolbachia deployments on notified
593 dengue cases and insecticide fogging for dengue control in Yogyakarta City. Glob
594 Health Action 16, 2166650.

595

596 Jeffries, C.L., Lawrence, G.G., Golovko, G., Kristan, M., Orsborne, J., Spence, K.,
597 Hurn, E., Bandibabone, J., Tantely, L.M., Raharimalala, F.N., Keita, K., Camara,
598 D., Barry, Y., Wat'senga, F., Manzambi, E.Z., Afrane, Y.A., Mohammed, A.R.,
599 Abeku, T.A., Hedge, S., Khanipov, K., Pimenova, M., Fofanov, Y., Boyer, S., Irish,
600 S.R., Hughes, G.L., and Walker, T. (2018). Novel Wolbachia strains in Anopheles
601 malaria vectors from Sub-Saharan Africa. Wellcome Open Res 3, 113.

602

603 Jiménez, N.E., Gerdtzen, Z.P., Olivera-Nappa, Á., Salgado, J.C., and Conca, C.
604 (2021). Novel Symbiotic Genome-Scale Model Reveals Wolbachia's Arboviral
605 Pathogen Blocking Mechanism in Aedes aegypti. mBio 12, e0156321.

606

607 Jin, C., Ren, X., and Rasgon, J.L. (2009). The virulent Wolbachia strain wMelPop
608 efficiently establishes somatic infections in the malaria vector Anopheles
609 gambiae. Appl Environ Microbiol 75, 3373-3376.

610

611 Kambris, Z., Cook, P.E., Phuc, H.K., and Sinkins, S.P. (2009). Immune activation
612 by life-shortening Wolbachia and reduced filarial competence in mosquitoes.
613 Science 326, 134-136.

614

615 Li, Y., Wang, Y., Chen, Y., Wang, Y., Zhang, S., Liu, P., Chen, Z., Song, P., Luo, L.,
616 Luo, Y., *et al.* (2020). Corilagin Ameliorates Atherosclerosis in Peripheral Artery
617 Disease via the Toll-Like Receptor-4 Signaling Pathway in vitro and in vivo. *Front*
618 *Immunol* 11, 1611.

619

620 Luckhart, S., Giulivi, C., Drexler, A.L., Antonova-Koch, Y., Sakaguchi, D., Napoli,
621 E., Wong, S., Price, M.S., Eigenheer, R., Phinney, B.S., *et al.* (2013). Sustained
622 activation of Akt elicits mitochondrial dysfunction to block *Plasmodium falciparum*
623 infection in the mosquito host. *PLoS Pathog* 9, e1003180.

624

625 Marinotti, O., Capurro Mde, L., Nirmala, X., Calvo, E., and James, A.A. (2006).
626 Structure and expression of the lipophorin-encoding gene of the malaria vector,
627 *Anopheles gambiae*. *Comp Biochem Physiol B Biochem Mol Biol* 144, 101-109.

628

629 Mendes, A.M., Schlegelmilch, T., Cohuet, A., Awono-Ambene, P., De Iorio, M.,
630 Fontenille, D., Morlais, I., Christophides, G.K., Kafatos, F.C., and Vlachou, D.
631 (2008). Conserved mosquito/parasite interactions affect development of
632 *Plasmodium falciparum* in Africa. *PLoS Pathog* 4, e1000069.

633

634 Michelsen, K.S., Doherty, T.M., Shah, P.K., and Arditi, M. (2004). TLR signaling:
635 an emerging bridge from innate immunity to atherogenesis. *J Immunol* 173,
636 5901-5907.

637

638 Molina-Cruz, A., DeJong, R.J., Charles, B., Gupta, L., Kumar, S., Jaramillo-
639 Gutierrez, G., and Barillas-Mury, C. (2008). Reactive oxygen species modulate
640 *Anopheles gambiae* immunity against bacteria and *Plasmodium*. *J Biol Chem*
641 283, 3217-3223.

642

643 Moreira, L.A., Iturbe-Ormaetxe, I., Jeffery, J.A., Lu, G., Pyke, A.T., Hedges, L.M.,
644 Rocha, B.C., Hall-Mendelin, S., Day, A., Riegler, M., *et al.* (2009). A *Wolbachia*
645 symbiont in *Aedes aegypti* limits infection with dengue, Chikungunya, and

646 Plasmodium. *Cell* 139, 1268-1278.

647

648 Murdock, C.C., Blanford, S., Hughes, G.L., Rasgon, J.L., and Thomas, M.B.
649 (2014). Temperature alters Plasmodium blocking by Wolbachia. *Sci Rep* 4, 3932.

650

651 Muroi, M., Ohnishi, T., and Tanamoto, K. (2002). Regions of the mouse CD14
652 molecule required for toll-like receptor 2- and 4-mediated activation of NF-kappa
653 B. *J Biol Chem* 277, 42372-42379.

654

655 Paiva, C.N., and Bozza, M.T. (2014). Are reactive oxygen species always
656 detrimental to pathogens? *Antioxid Redox Signal* 20, 1000-1037.

657

658 Pan, X., Zhou, G., Wu, J., Bian, G., Lu, P., Raikhel, A.S., and Xi, Z. (2012).
659 Wolbachia induces reactive oxygen species (ROS)-dependent activation of the
660 Toll pathway to control dengue virus in the mosquito *Aedes aegypti*. *Proc Natl*
661 *Acad Sci U S A* 109, E23-31.

662

663 Pujhari, S., Brustolin, M., Heu, C.C., Smithwick, R., Larrosa, M., Hafenstein, S.,
664 and Rasgon, J.L. (2022) Characterization of Mayaro virus (strain BeAn343102)
665 biology in vertebrate and invertebrate cellular backgrounds. *J Gen Virol* 103,
666 001794.

667

668 Quek, S., Cerdeira, L., Jeffries, C.L., Tomlinson, S., Walker, T., Hughes, G.L.,
669 Heinz, E. (2022) Wolbachia endosymbionts in two *Anopheles* species indicates
670 independent acquisitions and lack of prophage elements. *Microb Genom* 8,
671 000805.

672

673 Rainey, S.M., Shah, P., Kohl, A., and Dietrich, I. (2014). Understanding the
674 Wolbachia-mediated inhibition of arboviruses in mosquitoes: progress and
675 challenges. *J Gen Virol* 95, 517-530.

676

- 677 Rances, E., Johnson, T.K., Popovici, J., Iturbe-Ormaetxe, I., Zakir, T., Warr, C.G.,
678 and O'Neill, S.L. (2013). The toll and Imd pathways are not required for
679 wolbachia-mediated dengue virus interference. *J Virol* 87, 11945-11949.
680
- 681 Rances, E., Ye, Y.H., Woolfit, M., McGraw, E.A., and O'Neill, S.L. (2012). The
682 relative importance of innate immune priming in Wolbachia-mediated dengue
683 interference. *PLoS Pathog* 8, e1002548.
684
- 685 Rasgon, J.L., Ren, X., and Petridis, M. (2006) Can *Anopheles gambiae* be
686 infected with *Wolbachia pipientis*? Insights from an in vitro system. *Appl Environ*
687 *Microbiol* 72, 7718-7722.
688
- 689 Sandiford, S.L., Dong, Y., Pike, A., Blumberg, B.J., Bahia, A.C., and Dimopoulos,
690 G. (2015). Cytoplasmic actin is an extracellular insect immune factor which is
691 secreted upon immune challenge and mediates phagocytosis and direct killing of
692 bacteria, and is a Plasmodium Antagonist. *PLoS Pathog* 11, e1004631.
693
- 694 Shapiro, J.P. (1988). Lipid transport in insects. *Annu Rev Entomol* 33, 297–318.
695
- 696 Smith, L.L. (1991). Another cholesterol hypothesis: cholesterol as antioxidant.
697 *Free Radic Biol Med* 11, 47-61.
698
- 699 Teixeira, L., Ferreira, A., and Ashburner, M. (2008). The bacterial symbiont
700 *Wolbachia* induces resistance to RNA viral infections in *Drosophila melanogaster*.
701 *PLoS Biol* 6, e2.
702
- 703 Terradas, G., Novelo, M., Metz, H., Brustolin, M., and Rasgon, J.L. (2022)
704 *Anopheles albimanus* is a Potential Alphavirus Vector in the Americas. *Am J Trop*
705 *Med Hyg.* 108, 412-423.
706
- 707 Utarini, A., Indriani, C., Ahmad, R.A., Tantowijoyo, W., Arguni, E., Ansari, M.R.,

708 Supriyati, E., Wardana, D.S., Meitika, Y., Ernesia, I., Nurhayati, I., Prabowo, E.,
709 Andari, B., Green, B.R., Hodgson, L., Cutcher, Z., Rancès, E., Ryan, P.A., O'Neill,
710 S.L., Dufault, S.M., Tanamas, S.K., Jewell, N.P., Anders, K.L., Simmons, C.P.;
711 AWED Study Group. (2021) Efficacy of Wolbachia-Infected Mosquito
712 Deployments for the Control of Dengue. *N Engl J Med* 10, 2177-2186.

713

714 van der Vorst, E.P.C., Theodorou, K., Wu, Y., Hoeksema, M.A., Goossens, P.,
715 Bursill, C.A., Aliyev, T., Huitema, L.F.A., Tas, S.W., Wolfs, I.M.J., *et al.* (2017).
716 High-Density Lipoproteins Exert Pro-inflammatory Effects on Macrophages via
717 Passive Cholesterol Depletion and PKC-NF-kappaB/STAT1-IRF1 Signaling. *Cell*
718 *Metab* 25, 197-207.

719

720 Varshney, P., Yadav, V., and Saini, N. (2016). Lipid rafts in immune signalling:
721 current progress and future perspective. *Immunology* 149, 13-24.

722

723 Waldock, J., Olson, K.E., and Christophides, G.K. (2012). *Anopheles gambiae*
724 antiviral immune response to systemic O'nyong-nyong infection. *PLoS Negl Trop*
725 *Dis* 6, e1565.

726

727 Walker, T., Johnson, P.H., Moreira, L.A., Iturbe-Ormaetxe, I., Frentiu, F.D.,
728 McMeniman, C.J., Leong, Y.S., Dong, Y., Axford, J., Kriesner, P., *et al.* (2011).
729 The wMel Wolbachia strain blocks dengue and invades caged *Aedes aegypti*
730 populations. *Nature* 476, 450-453.

731

732 Walker, T., Quek, S., Jeffries, C.L., Bandibabone, J., Dhokiya, V., Bamou, R.,
733 Kristan, M., Messenger, L.A., Gidley, A., Hornett, E.A., Anderson, E.R., Cansado-
734 Utrilla, C., Hegde, S., Bantuzeko, C., Stevenson, J.C., Lobo, N.F., Wagstaff, S.C.,
735 Nkondjio, C.A., Irish, S.R., Heinz, E., and Hughes, G.L. (2021) Stable high-
736 density and maternally inherited Wolbachia infections in *Anopheles moucheti* and
737 *Anopheles demeilloni* mosquitoes. *Curr Biol* 31, 2310-2320.

738

739 Xi, Z., Ramirez, J.L., and Dimopoulos, G. (2008). The *Aedes aegypti* toll pathway
740 controls dengue virus infection. *PLoS Pathog* 4, e1000098.

741

742 Xu, X.H., Shah, P.K., Faure, E., Equils, O., Thomas, L., Fishbein, M.C.,
743 Luthringer, D., Xu, X.P., Rajavashisth, T.B., Yano, J., *et al.* (2001). Toll-like
744 receptor-4 is expressed by macrophages in murine and human lipid-rich
745 atherosclerotic plaques and upregulated by oxidized LDL. *Circulation* 104, 3103-
746 3108.

747

748 Yu, B.L., Wang, S.H., Peng, D.Q., and Zhao, S.P. (2010). HDL and
749 immunomodulation: an emerging role of HDL against atherosclerosis. *Immunol*
750 *Cell Biol* 88, 285-290.

751

752 Zele, F., Nicot, A., Berthomieu, A., Weill, M., Duron, O., and Rivero, A. (2014).
753 *Wolbachia* increases susceptibility to *Plasmodium* infection in a natural system.
754 *Proc Biol Sci* 281, 20132837.

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771 **Figure legends.**

772 **Fig.1. *Wolbachia* infection in *Anopheles gambiae* cells and inhibition of**

773 **ONNV.** A. Fluorescent *in situ* hybridization (FISH) of *Wolbachia* strains wMel and

774 wAlbB in infected Sua5B cells, gene-specific qPCR and melt curves, and

775 resolution of PCR products on a gel, confirming cellular infection. B. Infectious

776 ONNV titer in *Wolbachia* infected or uninfected Sua5B cell culture supernatants;

777 both *Wolbachia* strains wAlbB and wMel significantly inhibit virus. C. ONNV is

778 negatively correlated with *Wolbachia* density. As *Wolbachia* titers decrease due

779 to antibiotic treatment, ONNV increases. Treatments with different letters are

780 significantly different.

781

782 **Fig.2.** Transient somatic *Wolbachia* infections (wAlbB and wMel) inhibit ONNV in

783 A. *An. gambiae* and B. *An. stephensi* mosquitoes *in vivo*. Treatments with

784 different letters are significantly different.

785

786 **Fig.3. Interactions between *Wolbachia*, cholesterol, mosquito innate**

787 **immunity, and ONNV.** A. Effect of immune gene knock-down in wAlbB-infected

788 cells on ONNV titers. Depletion of *LYSC4*, *ML1* or *TOLL5A* (or *ML1* + *TOLL5A*

789 double KD) ablates *Wolbachia*-induced ONNV inhibition, while reactivation of the

790 Toll pathway through *cactus* knock-down completely restores the inhibition
791 phenotype. B. Cholesterol inhibits *Wolbachia*-induced ONNV inhibition in a dose-
792 dependent manner, but has no effect on ONNV levels in *Wolbachia*-uninfected
793 cells. C. Cholesterol supplementation suppresses *TOLL5A* expression in wAlbB-
794 infected but not *Wolbachia*-uninfected cells. While *Wolbachia* induces *IMD*, there
795 is no effect of cholesterol on *IMD* expression in *Wolbachia* infected or uninfected
796 cells. D. Cholesterol sequestration induces *TOLL5A* expression in wAlbB-infected
797 and uninfected cells, and the effect is synergistic with *Wolbachia*, but has no
798 effect on *IMD* expression. E. Cholesterol supplementation eliminates *cactus*-
799 based reactivation of Toll signaling and *Wolbachia*-mediated suppression of
800 ONNV in a dose-dependent manner. F. Cholesterol supplementation partially
801 ablates *Wolbachia*-induced inhibition of ONNV *in vivo* in *An. gambiae*.
802 Treatments with different letters are significantly different.

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817 **Supplementary Table 1. Primers used in this study.**

Primer	RefSeq ID	Sequence	
		RNAi	Real-time PCR
AgML1-T7	XM_320203.4	F- <u>GAATTAATACGACTCACTATTAGGG</u> GAAATGTCCGGTGAAAGAGA R- <u>GAATTAATACGACTCACTATTAGGG</u> CCACCAAGCATTGTTTAGT	F- GTCGCTATTGTGGCATTGTG R- AAAGTTTACTACTTCTGCCAAGC
AgLYSC4-T7	XM308448.3	F- <u>GAATTAATACGACTCACTATTAGGG</u> AGAGAAGACGGTGAATCGGGTAA R- <u>GAATTAATACGACTCACTATTAGGG</u> GTCGTTCAAAAATCCTCGC	F- GATATCGAGTGTGCGAAGCA R- CAGATCGGGCAGTGTCTTTT
AgIMD-T7	XM_001688556.1	F- <u>GAATACGACTCACTATAG</u> GAAATTTCCCAAATGGTGTG R- <u>GAATACGACTCACTATAG</u> TGTGTAGATTGCTCGCTTC	F- CGAAGCTAGAGACCGATGCT R- ATTCCATTTTTCGTAGCAG
AgCactus-T7	XM_317542.4	F- <u>GAATTAATACGACTCACTATTAGGG</u> GAGATCCGCTCTACAC R- <u>GAATTAATACGACTCACTATTAGGG</u> GACCGTTCGGGTAA	F- GAA CGTTTCGACCGTTTGT R- TCA GAAACTGCTGTGGAACG
AgToll5A-T7	XM_560220.3	F- <u>GAATACGACTCACTATAGGG</u> AATGCTAAGCTTCGGGACA R- <u>GAATACGACTCACTATAGGG</u> CTTGGTGTACGCTTGAGCA	F- ATCGAAAGCGAAATGTCCAG R- GCCGAGAGCAGATCTACGAG
GFP-T7	No ID	F- <u>GAATTAATACGACTCACTATTAGGG</u> CATGGTGAGCAAAGGCGAG R- <u>GAATTAATACGACTCACTATTAGGG</u> CTTACTGTACAGCTCGTC	AgS7-F-CCATCCTGGAGGATCTGGTA AgS7-R-GATGGTGGTCTGCTGGTCT
AgS7	XM_314557.3		

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837 **Supplementary Figure Legends**

838

839 Figure S1. Confirmation of RNAi gene knockdown efficiency.

840

841 Figure S2. Dose-dependent cholesterol toxicity in Sua5B cells.

842

843 Figure S3. Dose-dependent methyl-beta-cyclodextrin toxicity in Sua5B cells.

844

845

846

Figure 1




Figure 2




Figure 3




Figure S1.




Figure S2.




Figure S3.

